SLC29A1 and acute myeloid leukemia: In this study, we investigated the association of FLT3-ITD gene mutation with bone marrow blast count, CD34, Cyclin D1 (a cell proliferation marker), Bcl-xL (an anti-apoptotic agent) and hENT1 (a cytarabine transporter) expressions that lead to poor prognosis and determine treatment outcomes in AML patients with this mutation.